Press Releases


Latest News


Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 4th World Parkinson Congress
Sep 12, 2016 | General Releases

Adamas Announces New Employment Inducement Grant
Sep 9, 2016 | General Releases

Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation
Aug 31, 2016 | General Releases

Adamas Reports Second Quarter 2016 Financial Results
Aug 4, 2016 | Financial Releases

Allergan and Adamas Announce New Expanded Indication for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
Jul 19, 2016 | General Releases

Adamas Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
Jun 29, 2016 | General Releases

Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders
Jun 22, 2016 | General Releases

Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients
Jun 13, 2016 | General Releases

Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson's and Movement Disorders
May 16, 2016 | General Releases

Adamas Reports First Quarter 2016 Financial Results
May 10, 2016 | Financial Releases

Pages:  1 2 3 4 5 6 7 8 9 10 11